AXGN
Signal
Mixed11
Price
1
Move-1.50%Negative session
Volume
1
Volume0.9× avgNormal activity
Technical
1
RSIRSI 60Momentum positive
PRICE
Prev Close
43.28
Open
43.17
Day Range42.12 – 43.28
42.12
43.28
52W Range9.22 – 45.83
9.22
45.83
91% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-66.6x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.29
Market-like
Performance
1D
+0.19%
5D
+4.24%
1M
+32.60%
3M
+26.48%
6M
+82.08%
YTD
+32.23%
1Y
+158.39%
Best: 1Y (+158.39%)
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +22% YoY · 75% gross margin
Valuation
FAIR
P/E not available
Health
STRONG
CR 7.1 · FCF $0.17/sh
Strong Buy
Key MetricsTTM
Market Cap$2.27B
Revenue TTM$238.10M
Net Income TTM-$31.45M
Free Cash Flow$8.93M
Gross Margin75.0%
Net Margin-13.2%
Operating Margin-3.8%
Return on Equity-20.7%
Return on Assets-10.9%
Debt / Equity0.08
Current Ratio7.10
EPS TTM$-0.61

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
2 strong1 watch3 concern
42/100
Liquidity
7.10Strong
Leverage
0.08Strong
Coverage
-0.6xConcern
ROE
-20.7%Concern
ROIC
-3.4%Concern
Cash
$36MWatch
ANALYST COVERAGE19 analysts
BUY
-6.2%downside to target
L $36.00
Med $40.00consensus
H $50.00
Buy
1684%
Hold
316%
16 Buy (84%)3 Hold (16%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 5 signals bullish
8/10
Technicals
RSI RangeRSI 60 — Bullish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 7.10 — healthy liquidity
Upcoming Events
EEarnings Report · Before OpenMay 5, 2026
Tomorrow
DEx-Dividend DateAug 2, 2026
In 90 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 61.9%

+64.6% vs SMA 50 · +166.4% vs SMA 200

Momentum

RSI59.6
Positive momentum, not extended
MACD+2.26
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$45.83+7.5%
Current
$42.63
EMA 50
$26.88-37.0%
EMA 200
$16.00-62.5%
52W Low
$9.22-78.4%
52-Week RangeNear 52-week high
$9.2291th %ile$45.83
Squeeze SetupVolume-based
Elevated Squeeze Setup

Strong accumulation on above-average volume. Buyers are absorbing supply aggressively — any positive catalyst could trigger a rapid covering move.

20-Day Money Flow
Acc days:10
Dist days:3
Edge:+7 acc
Volume Context
Avg Vol (50D)750K
Recent Vol (5D)
1.1M+45%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 7 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$224.4M
$224.1M$224.9M
$0.31
±13%
Moderate4
FY2026(current)
$270.9M
$270.7M$271.0M
+20.7%$0.49+57.5%
±17%
High6
FY2027
$318.6M
$313.6M$324.6M
+17.6%$0.70+44.2%
±15%
High7
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryAXGN
Last 8Q
+167.1%avg beat
Beat 5 of 8 quartersMissed 3 Estimates rising
+200%
Q3'24
+1067%
Q4'24
+100%
Q1'25
-100%
Q2'25
+100%
Q3'25
+33%
Q4'25
-21%
Q1'26
-42%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Devinney Erick WayneChief Innovati…
$171K
Mar 16
SELL
Wendell Amy McbrideDir
$147K
Dec 16
SELL
Wendell Amy McbrideDir
$599K
Dec 16
SELL
Wendell Amy McbrideDir
$535K
Dec 16
SELL
Weiler Kathy JohnsonDir
$539K
Dec 16
SELL
Weiler Kathy JohnsonDir
$645K
Dec 16
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
WASATCH ADVISORS LP
1.9M
2
Assenagon Asset Management S.A.
1.4M
3
Capricorn Fund Managers Ltd
688K
4
Artemis Investment Management LLP
350K
5
Stephens Investment Management Group LLC
248K
6
F&V Capital Management, LLC
177K
7
PERKINS CAPITAL MANAGEMENT INC
169K
8
PRIMORIS WEALTH ADVISORS, LLC
139K
News & Activity

AXGN News

20 articles · 4h ago

About

Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Industry
Surgical and Medical Instrument Manufacturing
Marc A. BeganExecutive Vice President, General Counsel & Chief Compliance Officer
Michael D. DalePresident, Chief Executive Officer & Director
Doris QuackenbushVice President of Sales
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
AXGN
$42.63+0.19%$2.3B+2021.5%-697.3%1500
$68.99-3.59%$13.3B+12626.1%-14525.8%1500
$518.66-0.71%$11.8B+43205.3%-3008.0%1500
$91.17+0.60%$11.5B+3288.2%-4239.0%1500
$182.03-1.59%$10.7B29.2+1871.5%680.1%1500
$223.70-0.59%$10.6B+6554.5%-2868.8%1500
$76.39+1.81%$10.5B51.8+2325815.3%-19.7%1500
Sector avg-0.55%40.5+342197.5%-3525.5%1500